Literature DB >> 11311122

Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression.

R Maitra1, P A Halpin, K H Karlson, R L Page, D Y Paik, M O Leavitt, B D Moyer, B A Stanton, J W Hamilton.   

Abstract

Previous studies have demonstrated that mitomycin C (MMC) and other DNA cross-linking agents can suppress MDR1 (multidrug resistance 1) gene expression and subsequent functional P-glycoprotein (Pgp) expression, whereas doxorubicin and other anthracyclines increase MDR1 gene expression. In the present study, with stably transfected Madin-Darby canine kidney C7 epithelial cells expressing a human Pgp tagged with green fluorescent protein under the proximal human MDR1 gene promoter, we demonstrated that MMC and doxorubicin have differential effects on Pgp expression and function. Doxorubicin caused a progressive increase in the cell-surface expression of Pgp and function. In contrast, MMC initially increased plasma membrane expression and function at a time when total cellular Pgp was constant and Pgp mRNA expression had been shown to be suppressed. This was followed by a rapid and sustained decrease in cell-surface expression at later times, presumably as a consequence of the initial decrease in mRNA expression. These studies imply that there are at least two independent chemosensitive steps that can alter Pgp biogenesis: one at the level of mRNA transcription and the other at the level of Pgp trafficking. Understanding the combined consequences of these two mechanisms might lead to novel chemotherapeutic approaches to overcoming drug resistance in human cancers by altering either Pgp mRNA expression or trafficking to the membrane.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311122      PMCID: PMC1221775          DOI: 10.1042/bj3550617

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

Review 1.  Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors.

Authors:  R S Kerbel; J Rak; H Kobayashi; M S Man; B St Croix; C H Graham
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

2.  Characterization of the basal and carcinogen regulatory elements of the rat mdr1b promoter.

Authors:  J A Silverman; B A Hill
Journal:  Mol Carcinog       Date:  1995-05       Impact factor: 4.784

Review 3.  Defective protein folding as a basis of human disease.

Authors:  P J Thomas; B H Qu; P L Pedersen
Journal:  Trends Biochem Sci       Date:  1995-11       Impact factor: 13.807

Review 4.  Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.

Authors:  A F List
Journal:  Leukemia       Date:  1996-06       Impact factor: 11.528

5.  Preferential effects of the chemotherapeutic DNA crosslinking agent mitomycin C on inducible gene expression in vivo.

Authors:  R M Caron; J W Hamilton
Journal:  Environ Mol Mutagen       Date:  1995       Impact factor: 3.216

6.  High-affinity monoclonal antibodies against P-glycoprotein.

Authors:  T Shi; J Wrin; J Reeder; D Liu; D B Ring
Journal:  Clin Immunol Immunopathol       Date:  1995-07

7.  Suppression of multi-drug resistance gene expression in the mouse liver by 1,4-bis[2,(3,5-dichloropyridyloxy)]benzene.

Authors:  A L Russell; C J Henderson; G Smith; C R Wolf
Journal:  Int J Cancer       Date:  1994-08-15       Impact factor: 7.396

Review 8.  Multidrug resistance proteins and other drug transport-related resistance to natural product agents.

Authors:  H J Broxterman; G Giaccone; J Lankelma
Journal:  Curr Opin Oncol       Date:  1995-11       Impact factor: 3.645

9.  Effects of the genotoxic carcinogen chromium(VI) on basal and hormone-inducible phosphoenolpyruvate carboxykinase gene expression in vivo: correlation with glucocorticoid- and developmentally regulated expression.

Authors:  J McCaffrey; C M Wolf; J W Hamilton
Journal:  Mol Carcinog       Date:  1994-08       Impact factor: 4.784

10.  The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR.

Authors:  C Li; M Ramjeesingh; E Reyes; T Jensen; X Chang; J M Rommens; C E Bear
Journal:  Nat Genet       Date:  1993-04       Impact factor: 38.330

View more
  10 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model.

Authors:  Kenneth T Luu; James A Uchizono
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

3.  Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Authors:  Valérie Gouazé-Andersson; Jing Y Yu; Adam J Kreitenberg; Alicja Bielawska; Armando E Giuliano; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2007-11-09

4.  Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.

Authors:  Siying Ye; Daniel P MacEachran; Joshua W Hamilton; George A O'Toole; Bruce A Stanton
Journal:  Am J Physiol Cell Physiol       Date:  2008-07-23       Impact factor: 4.249

5.  A mathematical feasibility argument for the use of aptamers in chemotherapy and imaging.

Authors:  Khalid Boushaba; Howard Levine; Marit Nilsen Hamilton
Journal:  Math Biosci       Date:  2009-06-18       Impact factor: 2.144

6.  Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.

Authors:  Talia Golan; Tal Grenader; Patricia Ohana; Yasmine Amitay; Hilary Shmeeda; Ninh M La-Beck; Esther Tahover; Raanan Berger; Alberto A Gabizon
Journal:  Cancer Med       Date:  2015-07-14       Impact factor: 4.452

7.  Drug-induced trafficking of p-glycoprotein in human brain capillary endothelial cells as demonstrated by exposure to mitomycin C.

Authors:  Andreas Noack; Sandra Noack; Andrea Hoffmann; Katia Maalouf; Manuela Buettner; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Dana Alms; Kerstin Römermann; Hassan Y Naim; Wolfgang Löscher
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

8.  Single-step assembly of polymer-lipid hybrid nanoparticles for mitomycin C delivery.

Authors:  Yunfeng Yi; Yang Li; Hongjie Wu; Mengmeng Jia; Xiangrui Yang; Heng Wei; Jinyan Lin; Shichao Wu; Yu Huang; Zhenqing Hou; Liya Xie
Journal:  Nanoscale Res Lett       Date:  2014-10-08       Impact factor: 4.703

9.  Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.

Authors:  Alberto Gabizon; Patricia Ohana; Yasmine Amitay; Jenny Gorin; Dina Tzemach; Lidia Mak; Hilary Shmeeda
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 10.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.